Explore
Validate
Learn
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA004145 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA004145, RRID:AB_1859546
- Product name
- Anti-AHNAK2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human AHNAK2, Gene description: AHNAK nucleoprotein 2, Alternative Gene Names: C14orf78, Validated applications: IHC, ICC, Uniprot ID: Q8IVF2, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor lines.
Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy
AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
AHNAK2 is a potential prognostic biomarker in patients with PDAC
Contribution of Antibody-based Protein Profiling to the Human Chromosome-centric Proteome Project (C-HPP)
Ogasawara N, Kano Y, Yoneyama Y, Kobayashi S, Watanabe S, Kirino S, Velez-Bravo FD, Hong Y, Ostapiuk A, Lutsik P, Onishi I, Yamauchi S, Hiraguri Y, Ito G, Kinugasa Y, Ohashi K, Watanabe M, Okamoto R, Tejpar S, Yui S
iScience 2024 Mar 15;27(3):109247
iScience 2024 Mar 15;27(3):109247
Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy
Koguchi D, Matsumoto K, Shimizu Y, Kobayashi M, Hirano S, Ikeda M, Sato Y, Iwamura M
Cancers 2021;13(8):1748
Cancers 2021;13(8):1748
AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
Zhang S, Lu Y, Qi L, Wang H, Wang Z, Cai Z, Pizzimenti S
BioMed Research International 2020;2020(1)
BioMed Research International 2020;2020(1)
AHNAK2 is a potential prognostic biomarker in patients with PDAC
Lu D, Wang J, Shi X, Yue B, Hao J
Oncotarget 2017;8(19):31775-31784
Oncotarget 2017;8(19):31775-31784
Contribution of Antibody-based Protein Profiling to the Human Chromosome-centric Proteome Project (C-HPP)
Fagerberg L, Oksvold P, Skogs M, Älgenäs C, Lundberg E, Pontén F, Sivertsson Å, Odeberg J, Klevebring D, Kampf C, Asplund A, Sjöstedt E, Al-Khalili Szigyarto C, Edqvist P, Olsson I, Rydberg U, Hudson P, Ottosson Takanen J, Berling H, Björling L, Tegel H, Rockberg J, Nilsson P, Navani S, Jirström K, Mulder J, Schwenk J, Zwahlen M, Hober S, Forsberg M, von Feilitzen K, Uhlén M
Journal of Proteome Research 2012;12(6):2439-2448
Journal of Proteome Research 2012;12(6):2439-2448
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human skin and liver tissues using HPA004145 antibody. Corresponding AHNAK2 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
